
Azacitidine Program in Pharmaceutical Benefits Scheme (PBS) 012-18051104

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised azacitidine for
patients with acute myeloid leukaemia (AML), chronic myelomonocytic
leukaemia (CMML) or myelodysplastic syndrome (MDS).

Note: this page has been decommissioned and is for information only. See
AML, CMML and the MDS programs for current information.

Azacitidine and listing dates

Azacitidine (AZA) treats acute myeloid leukaemia, chronic myelomonocytic
leukaemia and myelodysplastic syndrome.

Listing dates are:

-   azacitidine - 1 February 2011

For more information see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to contact details, item and
restriction codes, the PBS schedule and the Services Australia website.

Related links

Manage work items in PaNDA

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
